» Articles » PMID: 6367043

Effects of Cyclosporine Immunosuppression in Insulin-dependent Diabetes Mellitus of Recent Onset

Overview
Journal Science
Specialty Science
Date 1984 Mar 30
PMID 6367043
Citations 140
Authors
Affiliations
Soon will be listed here.
Abstract

Type I diabetes may be an autoimmune disorder, although the evidence is largely circumstantial. The natural history of the disease after diagnosis includes partial remission in most patients, but only about 3 percent achieve transient insulin independence. beta Cell function, as indicated by the plasma concentration of C-peptide, is lost over 6 to 30 months and islet cell antibodies disappeared over 1 to 2 years. This article describes a pilot study in which 41 patients were treated with the immunosuppressive agent cyclosporine for 2 to 12 months. Of 30 patients treated within 6 weeks of diagnosis, 16 became insulin independent with concentrations of plasma C-peptide in the normal range and decreasing titers of islet cell antibodies. Of 11 patients who entered the study 8 to 44 weeks after diagnosis, two achieved this state. These results indicate that a controlled trial of the effects of cyclosporine in type I diabetes should be conducted.

Citing Articles

Identifying Promising Immunomodulators for Type 1 Diabetes (T1D) and Islet Transplantation.

Ajmal N, Bogart M, Khan P, Max-Harry I, Healy A, Nunemaker C J Diabetes Res. 2024; 2024:5151171.

PMID: 39735417 PMC: 11679277. DOI: 10.1155/jdr/5151171.


Insulitis in Human Type 1 Diabetic Pancreas: From Stem Cell Grafting to Islet Organoids for a Successful Cell-Based Therapy.

La Noce M, Nicoletti G, Papaccio G, Del Vecchio V, Papaccio F Cells. 2022; 11(23).

PMID: 36497199 PMC: 9740394. DOI: 10.3390/cells11233941.


From Disease and Patient Heterogeneity to Precision Medicine in Type 1 Diabetes.

den Hollander N, Roep B Front Med (Lausanne). 2022; 9:932086.

PMID: 35903316 PMC: 9314738. DOI: 10.3389/fmed.2022.932086.


100 years post-insulin: immunotherapy as the next frontier in type 1 diabetes.

Pearson J, McKinney E, Walker L Immunother Adv. 2022; 1(1):ltab024.

PMID: 35156097 PMC: 8826223. DOI: 10.1093/immadv/ltab024.


Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes.

Wilhelm-Benartzi C, Miller S, Bruggraber S, Picton D, Wilson M, Gatley K BMJ Open. 2021; 11(12):e053669.

PMID: 34876434 PMC: 8655536. DOI: 10.1136/bmjopen-2021-053669.